帕尔博西克利布:随机研究和现实世界的证据作为转移性乳腺癌治疗计划的基础
Eugen Ruckhäberle1, Marcus Schmidt2, Anja Welt3
1Universitätsfrauenklinik Düsseldorf, Heinrich-Heine-Universität, CIO ABCD, Düsseldorf, Germany.
Geburtshilfe und Frauenheilkunde
|September 4, 2024
概括
与内分泌疗法结合的Palbociclib是转移性乳腺癌的第一线治疗方法. 本综述审查了其在现实实践中的有效性,安全性和耐受性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 基于内分泌的联合治疗与CDK4/6抑制剂是HR+/HER2-高级或转移性乳腺癌 (mBC) 的标准第一线治疗方法.
- 作为最初的CDK4/6抑制剂的Palbociclib在随机对照试验 (RCT) 中已经证明了有效性和安全性.
研究的目的:
- 审查和总结关于mBC中的palbociclib的RCT和现实世界的证据 (RWE) 的证据.
- 在特定患者群体中批判性地讨论临床方面,包括安全性,耐受性,生活质量和疗效.
主要方法:
- 随机对照试验 (RCT) 的系统审查.
- 分析现实世界的证据 (RWE) 研究.
- 专注于临床相关的结果和患者特征.
主要成果:
- 帕尔博西克利布在HR+/HER2-mBC中表现出一致的疗效和良好的耐受性.
- 现实世界的数据支持了关于palbociclib的有效性和安全性概况的RCT的发现.
- 证据强调了palbociclib在改善患者治疗结果方面的重要性.
结论:
- 帕尔博西克利布仍然是HR+/HER2-mBC的第一线内分泌治疗的基石.
- 对RCT和RWE的全面审查支持其在临床实践中既定的作用.
- 这些证据有助于优化对mBC患者的治疗决策.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334


